Inventor · disambiguated record
Olivier Danos
Also filed as: DANOS OLIVIER · DANOS OLIVIER F
17 granted patents·35 pending applications·558 citations·filing 1983–2025
94Inventor score
Top patents by PatentIndex Score
52 records- 0192US5906817ABiocompatible implant for the expression and in vivo secretion of a therapeutic substancePASTEUR INSTITUT·Filed 1994·Granted May 25, 1999·171 cites·35 claims
- 0291US6936243B2Adeno-associated viral vector-mediated delivery of DNA to cells of the liverCELL GENESYS INC·Filed 2000·Granted Aug 30, 2005·36 cites·5 claims
- 0389US5449614ARecombinant retroviruses with amphotropic and ecotropic host rangesWHITEHEAD INSTITUE FOR BIOMEDI·Filed 1994·Granted Sep 12, 1995·149 cites·28 claims
- 0485US6440657B1Nucleic acids and peptides of human immunodeficiency virus type (HIV-1)PASTEUR INSTITUT·Filed 2000·Granted Aug 27, 2002·9 cites·6 claims
- 0584US4551270ADNA Fragments coding for polypeptides containing at least one antigenic determinant of the papillomavirus, particularly of the HPV 1a type and corresponding polypeptidesPASTEUR INSTITUT·Filed 1983·Granted Nov 5, 1985·77 cites·5 claims
- 0683US10494646B2Regulation of gene expression by aptamer-mediated modulation of alternative splicingMEIRAGTX UK II LTD·Filed 2016·Granted Dec 3, 2019·6 cites·17 claims
- 0782US5955331ARecombinant retroviruses with amphotropic and ecotropic host rangesWHITEHEAD BIOMEDICAL INST·Filed 1995·Granted Sep 21, 1999·47 cites·17 claims
- 0879US9290748B2Use of endonucleases for inserting transgenes into safe harbor lociDANOS OLIVIER·Filed 2011·Granted Mar 22, 2016·8 cites·8 claims
- 0979US2025388931A1Regulation of gene expression by aptamer-mediated modulation of alternative splicingMEIRAGTX GENE REGULATION LTD·Filed 2025·Application pending·0 cites
- 1077US11248239B2Regulation of gene expression by aptamer-mediated modulation of alternative splicingMEIRAGTX UK II LTD·Filed 2019·Granted Feb 15, 2022·2 cites·24 claims
- 1176US2025367326A1Microdystrophin nucleic acid gene therapy constructs and uses thereofREGENXBIO INC·Filed 2025·Application pending·0 cites
- 1276US2025367328A1Methods of manufacturing microdystrophin gene therapy constructsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 1376US2025367327A1Treatment of dystrophinopathies with microdystrophin gene therapy constructsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 1473US12359199B2Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymesMEIRAGTX UK II LTD·Filed 2022·Granted Jul 15, 2025·0 cites·25 claims
- 1572US12416018B2Regulation of gene expression by aptamer-mediated modulation of alternative splicingMEIRAGTX GENE REGULATION LTD·Filed 2022·Granted Sep 16, 2025·0 cites·43 claims
- 1672US6464998B1Composition for the in vivo production of therapeutic productsAVENTIS PHARMA SA·Filed 1994·Granted Oct 15, 2002·28 cites·25 claims
- 1770US2025312492A1Microdystrophin gene therapy administration for treatment of dystrophinopathiesREGENXBIO INC·Filed 2025·Application pending·0 cites
- 1868US5843638ANucleic acids and pepties of human immunodeficiency virus type-1 (HIV-1).PASTEUR INSTITUT·Filed 1995·Granted Dec 1, 1998·15 cites·1 claims
- 1965US2024216543A1Microdystrophin gene therapy administration for treatment of dystrophinopathiesREGENXBIO INC·Filed 2022·Application pending·0 cites
- 2065US2025249127A1Gene therapy for treating an ocular diseaseREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2163US2023270886A1Microdystrophin gene therapy constructs and uses thereofREGENXBIO INC·Filed 2020·Application pending·0 cites
- 2261US2025277004A1Hybrid aav capsidsREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2360US2025288697A1Vectorized anti-tnf-alpha inhibitors for ocular indicationsREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2459US2025207126A1Modified muscle-specific promotersREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2558US2024358857A1Treatment of duchenne muscular dystrophy and combinations thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 2657US2025276097A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 2757US2023227829A1Methods and compositions for treating epilepsyINST NAT SANTE RECH MED·Filed 2023·Application pending·0 cites
- 2856US2025001006A1Recombinant adeno-associated viruses for targeted deliveryREGENXBIO INC·Filed 2022·Application pending·0 cites
- 2956US2024384292A1Vectorized tnf-alpha antagonists for ocular indicationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 3056US2023323366A1Compounds for use in the treatment of epilepsyINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 3156US2024409955A1Auf1 combination therapies for treatment of muscle degenerative diseaseUNIV NEW YORK·Filed 2022·Application pending·0 cites
- 3255US11697815B2Regulation of gene expression through aptamer-modulated polyadenylationMEIRAGTX UK II LTD·Filed 2017·Granted Jul 11, 2023·0 cites·30 claims
- 3355US11512310B2Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymesMEIRAGTX UK II LTD·Filed 2017·Granted Nov 29, 2022·0 cites·23 claims
- 3455US2023124994A1Compositions and methods for the treatment of sanfilippo disease and other disordersLYSOGENE·Filed 2020·Application pending·0 cites
- 3555US2025179518A1Recombinant adeno-associated viruses for cns tropic deliveryREGENXBIO INC·Filed 2022·Application pending·0 cites
- 3655US2024417737A1Methods and compositions for treating epilepsyUNIQURE FRANCE·Filed 2022·Application pending·0 cites
- 3753US6326195B1Recombinant retroviral vectorPASTEUR INSTITUT·Filed 1999·Granted Dec 4, 2001·10 cites·16 claims
- 3853US2023381341A1Adeno-associated viruses for ocular delivery of gene therapyREGENXBIO INC·Filed 2021·Application pending·0 cites
- 3952US2023039652A1Methods for the treatment of epilepsyINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 4051US2023374541A1Recombinant adeno-associated viruses for cns or muscle deliveryREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4150US2022251567A1Methods for the treatment of epilepsyINST NAT SANTE RECH MED·Filed 2020·Application pending·0 cites
- 4250US2024018524A1Methods and compositions for treating epilepsyINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 4350US2023391864A1Vectorized anti-tnf-alpha antibodies for ocular indicationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4446US2020093939A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2019·Application pending·0 cites
- 4546US2002098223A1Biocompatible implant for the expression and in vivo secretion of a therapeutic substancePASTEUR INSTITUT·Filed 2001·Application pending·0 cites
- 4644US2022186256A1Recombinant adeno-associated viruses and uses thereofREGENXBIO INC·Filed 2020·Application pending·0 cites
- 4743US2022143221A1Gene Therapy For Eye PathologiesREGENXBIO INC·Filed 2020·Application pending·0 cites
- 4843US2022195462A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2020·Application pending·0 cites
- 4941US12247213B2Treatment of mucopolysaccharidosis IVAREGENXBIO INC·Filed 2019·Granted Mar 11, 2025·0 cites·16 claims
- 5037US2003100116A1Canine adenovirus vectors for the transfer of genes in targeted cellsFiled 2002·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Olivier Danos files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →